A low-intensity transcranial ultrasound stimulation device, developed by Sonomind SAS, was proven to be safe and effective in treating patients suffering from drug-resistant depression. The results of ...

In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral treatments for obesity, type 2 diabetes and ...

Researchers from Tongji University School of Medicine and collaborating institutions have discovered that NP65 plays a crucial role in maintaining normal visual function in mice. The study, published ...

Xenon Pharmaceuticals Inc. is delaying the phase III data readout from the X-tole2 trial with azetukalner in focal onset seizures (FOS) from the second half of 2025 to early 2026 but remains busy with ...

April may not have brought rain to med-tech, but tariffs and financial uncertainty certainly dampened the enthusiasm for IPOs. With those clouds lifting, three companies – Hinge Health Inc., ...

China’s National Medical Products Administration has approved Remegen Co. Ltd.’s antibody-drug conjugate (ADC), disitamab ...

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) were trading at $30.25, down $5.60, or 15%, on word of the delay of data from the phase III X-tole2 trial with azetukalner in focal onset seizures ...

Researchers from Trinity College Dublin, Princeton University and collaborators have discovered that blocking the uptake of ...

Ensoma Inc. has obtained IND clearance from the FDA for its lead program EN-374 in X-linked chronic granulomatous disease ...

Capsida Biotherapeutics Inc. has gained IND clearance from the FDA for CAP-002, its first-in-class, intravenously ...

Current therapies for chronic hepatitis B virus (HBV) infection can effectively suppress viral replication but do not achieve ...

A study has demonstrated the potential of a novel ligand-based CAR T-cell therapy for targeting CD7-positive T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell ...